That’s small intestinal fungal overgrowth. No, we don’t. We use the core antimicrobial protocol and will sometimes add A-FNG to it. The problem is that SIFO is entirely an empirical condition from diagnosis to treatment because, as you know, there’s no way diagnose it outside of a research setting. We’re just making an assumption that somebody has it. We’re also just kind of making assumptions on how to treat it because there is no research that we can refer to for treatment protocols as we can with SIBO, rifaximin and even botanicals and things like that. Currently, we just use empirically the core antimicrobial protocol plus A-FNG, sometimes molybdenum, Saccharomyces boulardii, and occasionally charcoal if the patient has a lot of issues with die-off related to fungal overgrowth.